ROIVANT SCIENCES LTD (ROIV)

BMG762791017 - Common Stock

12.55  -0.64 (-4.85%)

After market: 11.7 -0.85 (-6.77%)

ROIVANT SCIENCES LTD

NASDAQ:ROIV (9/28/2023, 7:11:12 PM)

After market: 11.7 -0.85 (-6.77%)

12.55

-0.64 (-4.85%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-14 2023-08-14/bmo
Earnings (Next)11-13 2023-11-13/amc
Ins Owners21.16%
Inst Owners15.37%
Market Cap9.69B
Shares771.74M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts83.75
IPO12-03 2020-12-03
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ROIV Daily chart

Company Profile

Roivant Sciences Ltd. engages in the biopharmaceutical business, which engages in the development of transformative medicine. The Company’s pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohn’s disease, in addition to various other therapies in various stages of clinical development. The firm advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. The company also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Company Info

ROIVANT SCIENCES LTD

7th Floor, 50 Broadway

London

P: 442074003347.0

Employees: 904

Website: http://roivant.com/

ROIV News

News Imagea day ago - The Motley FoolWhy Immunovant Stock Is Bolting Higher Today

The company may have best-in-class autoimmune disease therapy under its roof.

News Image2 days ago - Seeking AlphaImmunovant stock rallies for second day, fueled by public offering, drug data (IMVT)

Immunovant (IMVT) stock rallied for the second day, fueled by news it was planning to offer $300M of its common shares and positive data for its drug candidate IMVT-1402.

News Image2 days ago - InvezzRoivant stock price outlook: strong pipeline is a catalyst

Roivant Sciences (NASDAQ: ROIV) stock price surged on Tuesday as investors cheered the latest developments with Immunovant (NASDAQ: IMVT). The shares jumped by more than 20% and retested the year-to-date high of $12.90. They have soared by more than 390% from the lowest point in 2022. Encouraging Immunovant data Roivant Sciences is a biotech company, […]

News Image2 days ago - The Motley FoolWhy Shares of Immunovant Are Soaring on Tuesday

Immunovant sees strong potential for an autoimmune disorder therapy.

News Image2 days ago - ChartmillWhich stocks are moving on Tuesday?

Keep an eye on the top gainers and losers in Tuesday's session, as they reflect the most notable price movements.

News Image2 days ago - Seeking AlphaImmunovant drives OmniAb on IMVT-1402 data; argenx slips

OmniAb shares rise while argenx shares decline after Immunovant posts positive early-stage data for its autoimmune drug candidate, IMVT-1402. Read more here.

ROIV Twits

Here you can normally see the latest stock twits on ROIV, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example